Gallic acid
Die Produkte sind ausschließlich für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Wir verkaufen nicht an Patienten.
| Pack Size | Price | Availability | Quantity | Action |
|---|---|---|---|---|
| 10mM (in 1mL DMSO) | $12.00 | In Stock | 1 | |
| 25mg | $11.00 | In Stock | 1 | |
| 50mg | $21.00 | In Stock | 1 | |
| 100mg | $40.00 | In Stock | 1 | |
| 500mg | $56.00 | In Stock | 1 | |
| 1g | $84.00 | In Stock | 1 | |
| 5g | $160.00 | In Stock | 1 |
Zitate (Citations)
2 publicationsPublikationen von Forschern, die dieses Produkt verwendenBeschreibung (Description)
Gallic acid is a 3,4,5-trihydroxybenzoic acid phenolic compound with antioxidant, anti-inflammatory and antitumor activities. Gallic acid scavenges free radicals through phenolic hydroxyl groups and inhibits NF-κB and other inflammation-related pathways. Gallic acid is used for oxidative stress-related diseases, inflammatory responses and microbial infections[1-4].
In vitro, HeLa, H446 and SH-SY5Y cells were treated with 50µg/mL Gallic acid for 12 hours. Gallic acid induced iron-dependent cell death with apoptotic, ferroptotic and necroptotic features[5]. A549 and H1299 cells were treated with 0-400μM Gallic acid for 24-72 hours. Gallic acid decreased cell viability, inhibited cell proliferation and colony formation, induced G1/S phase cell cycle arrest, inhibited migration and invasion, triggered apoptosis and induced ferroptosis[6]. Caco-2 cells were pretreated with 1-10μg/mL Gallic acid for 24 hours and then stimulated with 10μg/mL LPS for 4 hours. Gallic acid increased Claudin-1, Occludin, ZO-1, Bcl-2 and IL-10 expression, decreased IL-6, IL-1β, TNF-α, iNOS, Bax and Bad expression, reduced ROS levels and restored SOD, CAT and GSH activities[7].
In vivo, diabetic C57BL/6J mice received daily oral gavage of 30mg/kg Gallic acid for 4 weeks. Gallic acid improved body weight and fasting blood glucose, reduced kidney-to-body ratio, serum urea, BUN, creatinine, urine protein and urine albumin, alleviated tubulointerstitial lesions and mesangial matrix expansion, reduced renal tissue ROS and MDA[8]. Rotenone-induced ICR mice received 50-100mg/kg Gallic acid by gavage every other day for 5 weeks. Gallic acid alleviated motor deficits, protected striatal and substantia nigra pars compacta neurons, maintained tyrosine hydroxylase-positive dopaminergic neurons, reduced reactive astrocyte activation in the substantia nigra pars compacta[9]. Middle cerebral artery occlusion (MCAO) C57BL/6J mice received intraperitoneal injection of 150mg/kg Gallic acid. Gallic acid improved neurological function scores, reduced cerebral infarct volume, brain water content and cerebral edema, protected neurons and reduced apoptosis[10].
References:[1] Weian W, Yunxin Y, Ziyan W, et al. Gallic acid: design of a pyrogallol-containing hydrogel and its biomedical applications. Biomater Sci. 2024 Mar 12;12(6):1405-1424.
[2] Tuli HS, Mistry H, Kaur G, et al. Gallic Acid: A Dietary Polyphenol that Exhibits Anti-neoplastic Activities by Modulating Multiple Oncogenic Targets. Anticancer Agents Med Chem. 2022;22(3):499-514.
[3] Fernandes FH, Salgado HR. Gallic Acid: Review of the Methods of Determination and Quantification. Crit Rev Anal Chem. 2016 May 3;46(3):257-65.
[4] Patil SB, Kulkarni YA. Role of gallic acid in the management of diabetes and its complications. Naunyn Schmiedebergs Arch Pharmacol. 2026 Mar;399(5):6239-6247.
[5] Tang HM, Cheung PCK. Gallic Acid Triggers Iron-Dependent Cell Death with Apoptotic, Ferroptotic, and Necroptotic Features. Toxins. 2019 Aug;11(9):492.
[6] Li B, Zhang J, Jiang Y, et al. Gallic acid: A promising anti-non-small cell lung cancer compound targeting early growth response protein-1 for apoptosis and ferroptosis. Phytomedicine. 2026;156:158220.
[7] Chu C, Ru H, Chen Y, et al. Gallic acid attenuates LPS-induced inflammation in Caco-2 cells by suppressing the activation of the NF-kB/MAPK signaling pathway. Acta Biochim Biophys Sin. 2024;56(6):905-15.
[8] Wang Y, Zhou D, Chen Q, et al. Reuterin alleviates Enterohemorrhagic Escherichia coli O157:H7-induced infectious diarrhea in mice through modulation of the gut microbiota. World J Microbiol Biotechnol. 2026;42:555.
[9] Thong-asa W, Wassana C, Sukkasem K, et al. Neuroprotective effect of gallic acid in mice with rotenone-induced neurodegeneration. Exp Anim. 2024;73(3):259-69.
[10] Hua W, Xu H, Chen R, et al. Gallic Acid Alleviates Cerebral Ischemia-reperfusion Injury in Mice by Mediating Microglial Polarization Through the NLRP3/mTOR Axis. J Neuroimmune Pharmacol. 2025;20:101.
Protokoll (Protocol)
| Cell experiment [1]: | |
|
Cell lines |
HeLa cells (human cervical cancer cell line), H446 cells (small cell lung cancer cell line), SH-SY5Y cells (neuroblastoma cell line) |
|
Preparation Method |
HeLa, H446 and SH-SY5Y cells were maintained in DMEM/F-12 or RPMI medium supplemented with 10% FBS at 37°C, 5% CO2. Cells were treated with Gallic acid at 50μg/mL for 12h, with live-cell staining of Hoechst 33342, NucView 530 Caspase-3 substrate, IncuCyte Cytotox Red and lipid peroxidation probe, followed by time-lapse confocal microscopy; cells were also co-treated with deferoxamine 200μM or necrosulfonamide 5μM. |
|
Reaction Conditions |
50μg/mL; 12h |
|
Applications |
Gallic acid induced nuclear condensation, mitochondrial fragmentation, cytochrome c release, caspase-3 activation, plasma membrane rupture, and lipid peroxidation in HeLa, H446 and SH-SY5Y cells. Gallic acid-induced cell death was suppressed by deferoxamine and accompanied by plasma membrane rupture suppression by necrosulfonamide with enhanced sensitivity to cell death. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6J male mice |
|
Preparation Method |
Eight-week-old C57BL/6J male mice were injected intraperitoneally with streptozotocin (65mg/kg) to induce diabetes, then diabetic mice were orally/gavaged or administered daily with Gallic acid (30mg/kg) alone for 4 weeks; kidney tissues and serum/urine samples were collected after 4 weeks for renal function tests, PAS/H&E staining, DHE staining, oxidative stress assays and Western blot of p-AMPK/SIRT1. |
|
Dosage form |
30mg/kg; daily; 4 weeks |
|
Applications |
Gallic acid increased body weight, reduced fasting blood glucose, kidney-to-body ratio, serum urea, BUN and creatinine, urine volume, urine albumin and urine total protein, and increased creatinine clearance in diabetic mice. Gallic acid reduced tubulointerstitial lesion score and mesangial matrix index, lowered renal ROS and MDA, restored SOD, CAT and GSH, and restored p-AMPK and SIRT1 levels in kidney tissues. |
| References: [1] Tang HM, Cheung PCK. Gallic Acid Triggers Iron-Dependent Cell Death with Apoptotic, Ferroptotic, and Necroptotic Features. Toxins. 2019 Aug;11(9):492. [2] Hong Y, Wang J, Sun W, et al. Gallic acid improves the metformin effects on diabetic kidney disease in mice. Renal Failure. 2023;45(1):2183726. | |
Produktdokumente (Product Documents)
Chemische Eigenschaften (Chemical Properties)
Rechner (Calculators)Molarität / Verdünnung / Molekulargewicht / Einheitenumrechnung / In-vivo-Formulierung / Löslichkeit
Reviews
Review for Gallic acid
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%